HomeCompareNNMX vs DGRO

NNMX vs DGRO: Dividend Comparison 2026

NNMX yields 1000000.00% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNMX wins by $4.7683925249533696e+36M in total portfolio value
10 years
NNMX
NNMX
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NNMX calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — NNMX vs DGRO

📍 NNMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNNMXDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NNMX + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NNMX pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNMX
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, NNMX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNMX + DGRO for your $10,000?

NNMX: 50%DGRO: 50%
100% DGRO50/50100% NNMX
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNMX buys
0
DGRO buys
0
No recent congressional trades found for NNMX or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNNMXDGRO
Forward yield1000000.00%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.7683925249533696e+36M$31.6K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$239.96
Total dividends collected$4.7683311610149396e+36M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NNMX vs DGRO ($10,000, DRIP)

YearNNMX PortfolioNNMX Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,293$213.22+$100.00MNNMX
2$934,786,450,701$934,679,439,252.34$12,730$217.32+$934786.44MNNMX
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,326$221.10+$8165787108.56MNNMX
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,098$224.56+$66665884190957.63MNNMX
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$18,064$227.74+$508662171058048128.00MNNMX
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$20,246$230.65+$3.62723524842849e+21MNNMX
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$22,666$233.30+$2.417368115915061e+25MNNMX
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$25,349$235.73+$1.5056740286145463e+29MNNMX
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$28,325$237.94+$8.764771002818475e+32MNNMX
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$31,624$239.96+$4.7683925249533696e+36MNNMX

NNMX vs DGRO: Complete Analysis 2026

NNMXStock

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.

Full NNMX Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this NNMX vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNMX vs SCHDNNMX vs JEPINNMX vs ONNMX vs KONNMX vs MAINNNMX vs VIGNNMX vs NOBLNNMX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.